New Frontiers in Subcutaneous Immunoglobulin Treatment

摘要: Subcutaneous immunoglobulin (SCIG) treatment provides stable serum G (IgG) levels, is associated with fewer systemic adverse events than intravenous (IVIG) treatment, and offers the convenience of home therapy. In clinical practice, IVIG still used preferentially for initiation in newly diagnosed patients primary immunodeficiency (PI) immunomodulatory therapy, such as peripheral neuropathies, when high doses are believed to be necessary. The authors discuss recent experience using SCIG place these settings. has been successfully therapy previously untreated PI patients. Seventeen 18 achieved IgG levels ≥5 g/L after loading phase. Daily was well tolerated provided opportunities patient/parent training self-infusion. maintenance multifocal motor neuropathy (MMN) three trials, good efficacy tolerability results. Seven eight MMN maintained 14–22 a mean dose 272 mg/kg/week, had muscle strength, felt comfortable self-administration. Four polymyositis or dermatomyositis improvement creatine kinase strength Recent suggests that traditional concepts may challenged increase available options. can achieve within several days maintain shown MMN.